1132 related articles for article (PubMed ID: 27581457)
61. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
[TBL] [Abstract][Full Text] [Related]
62. Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.
Gonzales KK; Smith Y
Ann N Y Acad Sci; 2015 Sep; 1349(1):1-45. PubMed ID: 25876458
[TBL] [Abstract][Full Text] [Related]
63. Chemogenetic Targeting of Dorsomedial Direct-pathway Striatal Projection Neurons Selectively Elicits Rotational Behavior in Mice.
Bay Kønig A; Ciriachi C; Gether U; Rickhag M
Neuroscience; 2019 Mar; 401():106-116. PubMed ID: 30668973
[TBL] [Abstract][Full Text] [Related]
64. [3H]acetycholine release in rat striatal slices is not subject to dopamine heteroreceptor supersensitivity 30 months after 6-hydroxydopamine lesion of the substantia nigra.
Löschmann PA; De Groote C; Albrecht C; Darstein M; Deransart C; Landwehrmeyer GB; Lücking CH; Feuerstein TJ
Naunyn Schmiedebergs Arch Pharmacol; 2001 Apr; 363(4):414-21. PubMed ID: 11330335
[TBL] [Abstract][Full Text] [Related]
65. M1 muscarinic acetylcholine receptor-mediated inhibition of GABA release from striatal medium spiny neurons onto cholinergic interneurons.
Suzuki E; Momiyama T
Eur J Neurosci; 2021 Feb; 53(3):796-813. PubMed ID: 33270289
[TBL] [Abstract][Full Text] [Related]
66. Blockade of M4 muscarinic receptors on striatal cholinergic interneurons normalizes striatal dopamine release in a mouse model of TOR1A dystonia.
Downs AM; Donsante Y; Jinnah HA; Hess EJ
Neurobiol Dis; 2022 Jun; 168():105699. PubMed ID: 35314320
[TBL] [Abstract][Full Text] [Related]
67. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
Wei W; Ding S; Zhou FM
J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
[TBL] [Abstract][Full Text] [Related]
68. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Nash JE; Brotchie JM
Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
[TBL] [Abstract][Full Text] [Related]
69. Striatal Cholinergic Interneurons in a Knock-in Mouse Model of L-DOPA-Responsive Dystonia.
Yalcin-Cakmakli G; Rose SJ; Villalba RM; Williams L; Jinnah HA; Hess EJ; Smith Y
Front Syst Neurosci; 2018; 12():28. PubMed ID: 29997483
[TBL] [Abstract][Full Text] [Related]
70. Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease.
Divito CB; Steece-Collier K; Case DT; Williams SP; Stancati JA; Zhi L; Rubio ME; Sortwell CE; Collier TJ; Sulzer D; Edwards RH; Zhang H; Seal RP
J Neurosci; 2015 Nov; 35(45):14983-99. PubMed ID: 26558771
[TBL] [Abstract][Full Text] [Related]
71. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
[TBL] [Abstract][Full Text] [Related]
72. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
73. Dopamine Cells Differentially Regulate Striatal Cholinergic Transmission across Regions through Corelease of Dopamine and Glutamate.
Cai Y; Ford CP
Cell Rep; 2018 Dec; 25(11):3148-3157.e3. PubMed ID: 30540946
[TBL] [Abstract][Full Text] [Related]
74. Loss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice.
Borgkvist A; Avegno EM; Wong MY; Kheirbek MA; Sonders MS; Hen R; Sulzer D
Neuron; 2015 Sep; 87(5):976-88. PubMed ID: 26335644
[TBL] [Abstract][Full Text] [Related]
75. Modulation of direct pathway striatal projection neurons by muscarinic M₄-type receptors.
Hernández-Flores T; Hernández-González O; Pérez-Ramírez MB; Lara-González E; Arias-García MA; Duhne M; Pérez-Burgos A; Prieto GA; Figueroa A; Galarraga E; Bargas J
Neuropharmacology; 2015 Feb; 89():232-44. PubMed ID: 25290553
[TBL] [Abstract][Full Text] [Related]
76. What's wrong with the striatal cholinergic interneurons in Parkinson's disease? Focus on intrinsic excitability.
Tubert C; Murer MG
Eur J Neurosci; 2021 Apr; 53(7):2100-2116. PubMed ID: 32302030
[TBL] [Abstract][Full Text] [Related]
77. Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons.
Dawson VL; Dawson TM; Wamsley JK
Brain Res Bull; 1990 Dec; 25(6):903-12. PubMed ID: 2149667
[TBL] [Abstract][Full Text] [Related]
78. Cellular and behavioral outcomes of dorsal striatonigral neuron ablation: new insights into striatal functions.
Révy D; Jaouen F; Salin P; Melon C; Chabbert D; Tafi E; Concetta L; Langa F; Amalric M; Kerkerian-Le Goff L; Marie H; Beurrier C
Neuropsychopharmacology; 2014 Oct; 39(11):2662-72. PubMed ID: 24903652
[TBL] [Abstract][Full Text] [Related]
79. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
80. The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia.
Nair AG; Castro LRV; El Khoury M; Gorgievski V; Giros B; Tzavara ET; Hellgren-Kotaleski J; Vincent P
Neuropharmacology; 2019 Mar; 146():74-83. PubMed ID: 30468798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
